MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

NCT06198868 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-01-12

No results posted yet for this study

Summary

This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.

Conditions

Interventions

PROCEDURE

Operable

Enrolled patients capable of surgical treatment

Sponsors & Collaborators

  • Jiangsu Cancer Institute & Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2026-02-01
Completion
2027-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06198868 on ClinicalTrials.gov